S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Sell every Stock except ONE (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
AP source: Biden, McCarthy reach final deal to prevent default, now must sell to Congress
Sell every Stock except ONE (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Sell every Stock except ONE (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Sell every Stock except ONE (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
AP source: Biden, McCarthy reach final deal to prevent default, now must sell to Congress
Sell every Stock except ONE (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Sell every Stock except ONE (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Sell every Stock except ONE (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
AP source: Biden, McCarthy reach final deal to prevent default, now must sell to Congress
Sell every Stock except ONE (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Sell every Stock except ONE (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Sell every Stock except ONE (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
AP source: Biden, McCarthy reach final deal to prevent default, now must sell to Congress
Sell every Stock except ONE (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Sell every Stock except ONE (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
NASDAQ:VRAY

ViewRay (VRAY) Stock Forecast, Price & News

$0.53
0.00 (0.00%)
(As of 05/26/2023 ET)
Compare
Today's Range
$0.53
$0.58
50-Day Range
$0.53
$3.50
52-Week Range
$0.51
$4.96
Volume
3.09 million shs
Average Volume
2.79 million shs
Market Capitalization
$97.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.18

ViewRay MarketRank™ Forecast

Analyst Rating
Hold
2.14 Rating Score
Upside/​Downside
500.0% Upside
$3.18 Price Target
Short Interest
Healthy
4.01% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.85
Upright™ Environmental Score
News Sentiment
0.63mentions of ViewRay in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$173,460 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.58) to ($0.49) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.52 out of 5 stars

Medical Sector

150th out of 1,012 stocks

Electromedical Equipment Industry

3rd out of 22 stocks


VRAY stock logo

About ViewRay (NASDAQ:VRAY) Stock

ViewRay, Inc. designs, manufactures, and markets the MRIdian MRI-guided Radiation Therapy System. It develops MRIdian to address the limitations of existing external-beam radiation therapy technologies and employs MRI-based technology to provide real-time imaging that defines the tumor from the surrounding soft tissue, and other critical organs, both before and during radiation treatment delivery. The company was founded by Dinara Akzhigitova in 2004 and is headquartered in Oakwood Village, OH.

Receive VRAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ViewRay and its competitors with MarketBeat's FREE daily newsletter.

VRAY Stock News Headlines

ViewRay (NASDAQ: VRAY)
Viewray (VRAY) Receives a Hold from Stifel Nicolaus
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
B.Riley Financial downgrades Viewray (VRAY) to a Hold
ViewRay (NASDAQ:VRAY) Downgraded by B. Riley
BTIG Remains a Hold on Viewray (VRAY)
ViewRay Announces First Quarter 2023 Results
ViewRay (NASDAQ:VRAY) PT Lowered to $2.00 at Piper Sandler
Jefferies Downgrades Viewray (VRAY)
Jefferies downgrades Viewray (VRAY) to a Hold
See More Headlines
Receive VRAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ViewRay and its competitors with MarketBeat's FREE daily newsletter.

VRAY Company Calendar

Last Earnings
5/10/2023
Today
5/28/2023
Next Earnings (Estimated)
8/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VRAY
Employees
267
Year Founded
2004

Price Target and Rating

Average Stock Price Forecast
$3.18
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
+500.0%
Consensus Rating
Hold
Rating Score (0-4)
2.14
Research Coverage
7 Analysts

Profitability

Net Income
$-107,330,000.00
Net Margins
-104.30%
Pretax Margin
-104.30%

Debt

Sales & Book Value

Annual Sales
$102.21 million
Book Value
$0.30 per share

Miscellaneous

Free Float
178,817,000
Market Cap
$97.17 million
Optionable
Optionable
Beta
0.91

Social Links


Key Executives

  • Scott William DrakeScott William Drake
    President, Chief Executive Officer & Director
  • Drew Hill
    Senior Vice President-Operations & Development
  • William Patrick Burke
    Chief Financial Officer & Executive Vice President
  • James F. Dempsey
    Chief Scientific Officer
  • Martin Fuss
    Chief Medical Officer













VRAY Stock - Frequently Asked Questions

Should I buy or sell ViewRay stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ViewRay in the last twelve months. There are currently 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" VRAY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VRAY, but not buy additional shares or sell existing shares.
View VRAY analyst ratings
or view top-rated stocks.

What is ViewRay's stock price forecast for 2023?

7 brokers have issued twelve-month price objectives for ViewRay's stock. Their VRAY share price forecasts range from $1.00 to $8.00. On average, they predict the company's stock price to reach $3.18 in the next year. This suggests a possible upside of 500.0% from the stock's current price.
View analysts price targets for VRAY
or view top-rated stocks among Wall Street analysts.

How have VRAY shares performed in 2023?

ViewRay's stock was trading at $4.48 on January 1st, 2023. Since then, VRAY stock has decreased by 88.2% and is now trading at $0.5298.
View the best growth stocks for 2023 here
.

When is ViewRay's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023.
View our VRAY earnings forecast
.

How were ViewRay's earnings last quarter?

ViewRay, Inc. (NASDAQ:VRAY) released its quarterly earnings data on Wednesday, May, 10th. The company reported ($0.16) EPS for the quarter, missing analysts' consensus estimates of ($0.15) by $0.01. The business had revenue of $22.53 million for the quarter, compared to analyst estimates of $22.64 million. ViewRay had a negative trailing twelve-month return on equity of 120.48% and a negative net margin of 104.30%.

What ETFs hold ViewRay's stock?
What guidance has ViewRay issued on next quarter's earnings?

ViewRay issued an update on its FY 2023 earnings guidance on Tuesday, April, 18th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $102.21 million-$117.54 million, compared to the consensus revenue estimate of $136.37 million.

What is Scott Drake's approval rating as ViewRay's CEO?

5 employees have rated ViewRay Chief Executive Officer Scott Drake on Glassdoor.com. Scott Drake has an approval rating of 59% among the company's employees. This puts Scott Drake in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ViewRay own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ViewRay investors own include Alibaba Group (BABA), Amarin (AMRN), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Viking Therapeutics (VKTX), AbbVie (ABBV), Accuray (ARAY) and Selecta Biosciences (SELB).

When did ViewRay IPO?

(VRAY) raised $52 million in an IPO on the week of April 6th 2015. The company issued 4,000,000 shares at $12.00-$14.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and BTIG and Brean Capital were co-managers.

What is ViewRay's stock symbol?

ViewRay trades on the NASDAQ under the ticker symbol "VRAY."

Who are ViewRay's major shareholders?

ViewRay's stock is owned by many different retail and institutional investors. Top institutional shareholders include Artisan Partners Limited Partnership (8.44%), Fosun International Ltd (6.60%), BlackRock Inc. (5.81%), Neuberger Berman Group LLC (5.63%), FMR LLC (2.90%) and Group One Trading L.P. (0.00%). Insiders that own company stock include Brian K Roberts, Caley Castelein, Influence Ltd Strong, International Ltd Fosun, James F Dempsey, Scott William Drake, Susan C Schnabel and Zachary William Stassen.
View institutional ownership trends
.

How do I buy shares of ViewRay?

Shares of VRAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ViewRay's stock price today?

One share of VRAY stock can currently be purchased for approximately $0.53.

How much money does ViewRay make?

ViewRay (NASDAQ:VRAY) has a market capitalization of $97.17 million and generates $102.21 million in revenue each year. The company earns $-107,330,000.00 in net income (profit) each year or ($0.60) on an earnings per share basis.

How many employees does ViewRay have?

The company employs 267 workers across the globe.

Does ViewRay have any subsidiaries?
The following companies are subsidiares of ViewRay: Vesuvius Acquisition Corp., ViewRay GmbH, and ViewRay Technologies Inc..
Read More
How can I contact ViewRay?

ViewRay's mailing address is 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH, 44146. The official website for the company is www.viewray.com. The company can be reached via phone at (440) 703-3210, via email at investors@viewray.com, or via fax at 800-417-3459.

This page (NASDAQ:VRAY) was last updated on 5/28/2023 by MarketBeat.com Staff

My Account -